While the separation and enumeration of CTCs has been validated for use in clinical practice [19], the molecular characterization of CTCs (including the HER2 status assessment) is still not well established, even though it represents a unique opportunity for a comprehensive characterization of the tumor in real-time, which cannot be achieved with any other liquid biopsy analytes. This evidence concerns the gene ERBB2 and neoplasm.